LEXICON PHARMACEUTICALS, INC. 8-K

What Happened

• Lexicon Pharmaceuticals (NASDAQ: LXRX) filed an 8-K on May 6, 2026 to disclose a loan and security agreement with Hercules Capital providing up to $100 million in term loan capacity, available in three tranches and maturing in May 2030. The first tranche of $55 million was funded at closing. The financing ties interest-only periods and later amortization to performance milestones tied to Lexicon’s SONATA‑HCM Phase 3 trial of sotagliflozin and to potential FDA approval.

Key Details

• Total facility: up to $100 million in three tranches (Tranche 1: $55M funded; Tranche 2: $20M available within 30 days after specified milestones but no later than June 15, 2028; Tranche 3: $25M available at Lexicon’s option with Hercules’ consent).
• Interest and fees: floating rate = prime + 3.10% but not less than 9.85%; initial interest-only payments for 18 months (may extend to 24 or 30 months if clinical/FDA milestones are met); prepayment fee ≈ 3.0% on declining scale; final payment equal to 6.25% of amount funded due at prepayment or maturity.
• Security and covenants: secured by a first‑lien on Lexicon’s assets; includes customary representations, affirmative/negative covenants and events of default; financial covenants include a minimum cash covenant effective June 1, 2027 (subject to extensions/waivers tied to milestones and market-cap tests) and a minimum revenue covenant that is triggered only after draws of later tranches.
• Equity-linked consideration: Hercules received warrants equal to 2% of the principal funded under the facility at $1.59 per share (net cashless exercise). Warrants issued at closing for Tranche 1: 691,823 shares; Tranche 2: 251,572 shares; Tranche 3: 314,465 shares. Issuances are unregistered and rely on Section 4(a)(2) and/or 3(a)(9) exemptions.

Why It Matters

• The facility provides immediate liquidity (the $55M funded) and potential additional capital tied to clinical and regulatory milestones for sotagliflozin in hypertrophic cardiomyopathy (HCM), which directly links financing availability to the company’s development progress. The interest rate floor (9.85%) and fees make this a relatively costly form of capital, and the loans are secured by Lexicon’s assets, which could limit flexibility. Warrants create potential equity dilution if exercised. Investors should note the covenant timing (minimum cash beginning mid‑2027 unless milestones/market cap conditions change) and milestone-based extensions that affect repayment timing.